NCT02390609 - A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Healthy

Interventions

DRUG

Ibrutinib (Treatment A) [Reference]

Participants will receive Ibrutinib 560 milligram (mg) (4\*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.

DRUG

Ibrutinib (Treatment B)

Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.

DRUG

Ibrutinib (Treatment C)

Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.

DRUG

Ibrutinib (Treatment D)

Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.

DRUG

Ibrutinib (Treatment E)

Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.

DRUG

Ibrutinib (Treatment F)

Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY